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South Africa (SA) has an extremely high proportion of pregnant 
women living with HIV.[1] The 2017 Antenatal Survey[2] reported a 
national prevalence of 30.7%, a rate that has remained fairly constant 
for the past decade.[2] This high maternal prevalence translates into 
~300 000 HIV-exposed infants born per annum, all of whom require 
HIV diagnostic services.[3] In 2004, SA implemented its national 
antiretroviral treatment (ART) programme, including specific 
interventions for prevention of mother-to-child transmission.[4] 
Since then, significant improvements in maternal and infant health 
outcomes have been achieved. One of the more marked successes 
has been reduction in the early infant HIV transmission rate from 
>20% to <2%.[4,5] However, on account of the considerable burden 
of maternal disease, the absolute number of HIV-infected infants 
and children remains high.[6] Routine early infant diagnosis (EID) 
services for all HIV-exposed infants therefore remain a cornerstone 
of paediatric HIV care.
Importantly, as the prevalence of a disease decreases, so too does the 
positive predictive value (PPV) of diagnostic assays. The changes in 
the HIV epidemic, including an increase in the proportion of people 
living with HIV who have been diagnosed and initiated on ART, and 
the corresponding decrease in the proportion of people living with 
HIV who are undiagnosed, have led to an increase in the proportion of 
false-positive test results. In response, the World Health Organization 
(WHO) recommends using different consecutive serological tests (i.e. 
rapid diagnostic tests and/or enzyme immunoassays) for individuals 
who initially test reactive in order to diagnose HIV, even in high-
burden settings.[7,8] However, owing to the trans-placental transfer of 
maternal antibodies, serological tests can only be used for diagnosis 
in adults and in children >18   months of age. To diagnose HIV in 
infants and children <18 months of age, nucleic acid tests (NATs) 
are recommended. However, instead of using consecutive assays 
to minimise false-positive results for infant diagnosis, the WHO 
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Background. The proportion of HIV-exposed infants and young children infected with HIV in South Africa (SA) has declined markedly 
over the past decade as a result of the country’s comprehensive prevention of mother-to-child transmission programme. This decrease has in 
turn reduced the positive predictive value (PPV) of diagnostic assays, necessitating review of early infant diagnosis (EID) algorithms to ensure 
improved accuracy.
Objectives. To evaluate the performance of the GeneXpert HIV-1 qualitative assay (Xpert EID) as a consecutive test for infants with an ‘HIV-
detected’ polymerase chain reaction screening test at birth.
Methods. We retrospectively analysed a longitudinal cohort of HIV-exposed infants on whom birth testing was performed, using whole-blood 
ethylenediaminetetra-acetic acid samples, from four tertiary sites in Gauteng Province between June 2014 and December 2019. Birth samples 
from all infants with a Cobas AmpliPrep/Cobas TaqMan HIV-1 Qualitative Test v2.0 (CAP/CTM v2.0) HIV-detected screening test, a concurrent 
Xpert EID test and a subsequent confirmatory CAP/CTM v2.0 test on a separate specimen were included. Performance of the Xpert EID in 
predicting final HIV status was determined as proportions with 95% confidence intervals (CIs). A comparison of indeterminate CAP/CTM 
v2.0 results, as per National Health Laboratory Service resulting practice, with discordant CAP/CTM v2.0 v. Xpert EID results was performed.
Results. Of 150 infants who met the inclusion criteria, 6 (3.9%) had an Xpert EID result discordant with final HIV status: 5 (3.3%) were false 
negatives and 1 (0.7%) was false positive. As a consecutive test, the Xpert EID yielded a sensitivity of 96.5% (95% CI 92 - 98.9), specificity of 
85.7% (95% CI 42.1 - 99.6), PPV of 99.3% (95% CI 95.7 - 99.9), negative predictive value of 54.5% (95% CI 32.5 - 74.9) and overall accuracy 
of 96.1% (95% CI 91.5 - 98.5). Using discordant CAP/CTM v2.0/Xpert EID results as criteria to verify indeterminate results instead of current 
practice would have reduced the number of indeterminate screening results by 42.1%, from 18 (12.6%) to 11 (7.2%), without increasing the 
false-positive rate.
Conclusions. Addition of the Xpert EID as a consecutive test for specimens with an HIV-detected PCR screening result has the potential to 
improve the PPV and reduce the indeterminate rate, thereby reducing diagnostic challenges and time to final status, in SA’s EID programme.
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recommends the use of an indeterminate range whereby potentially 
false-positive results can be differentiated from clearly positive cases. 
Additionally, guidelines recommend confirmatory testing on a second 
sample collected as early as possible after a positive or indeterminate 
screening test result.[9,10] A number of challenges with this diagnostic 
algorithm have been reported.[11] These include delays in making a final 
diagnosis as a result of exposure to infant antiretroviral prophylaxis 
and maternal treatment, both in utero and via breastfeeding, which 
can result in a marked reduction in viraemia and loss of HIV detection 
among infected infants.[12-16]
Commercially available EID assays are usually real-time polymerase 
chain reaction (PCR)-based NATs that report a cycle threshold (Ct) 
value. The Ct value refers to the number of thermal cycles required 
for the fluorescence signal of a test to cross the diagnostic threshold 
signifying an ‘HIV-detected’ or positive result. The Ct value is assay 
specific. Although the Ct value is usually inversely correlated with 
the amount of virus in a specimen,[17] tests yielding high Ct values are 
also more frequently associated with false-positive results. The WHO 
recommends a Ct ≥33 on the COBAS AmpliPrep/COBAS TaqMan 
HIV-1 Qualitative Test v2.0 (Roche Molecular Systems Inc., USA; 
hereafter referred to as CAP/CTM v2.0) as the optimal indeterminate 
range (i.e. for reporting an HIV-detected result as indeterminate 
instead of positive).[18] Without the use of an indeterminate range, it 
is estimated that >10% of infants could be incorrectly diagnosed as 
HIV-positive if their initial test result is not confirmed.[19]
In SA’s public health sector, only the CAP/CTM v2.0 and Cobas 
HIV-1/HIV-2 Qualitative Test assays are currently used for EID. 
HIV PCR testing is therefore restricted to EID assays from a single 
manufacturer. Results with a CAP/CTM v2.0 Ct >33 (or equivalent) 
and/or a relative fluorescence intensity (RFI) <5 are reported as 
indeterminate as per National Health Laboratory Service (NHLS) 
guidelines.[4] This reporting practice has been associated with a 
high indeterminate reporting rate. Seventeen percent of all HIV-
detected PCR results were reported as indeterminate between 2013 
and 2015, equating to ~3 000 tests annually.[20,21] The indeterminate 
rate among birth samples is even higher, at ~24%.[13] The high 
indeterminate reporting rate has in turn resulted in a high burden 
of missed diagnostic opportunities and delays in ART initiation 
in HIV-infected infants and children – especially considering that 
approximately half of infants with an indeterminate result at birth 
have been found to be HIV-infected on follow-up.[22]
Objectives
The high volume of indeterminate HIV PCR results in SA 
highlights the need to revise EID algorithms to ensure accurate 
and timely diagnosis. In this study, we evaluate the performance of 
the GeneXpert HIV-1 Qualitative Assay (Cepheid, USA; hereafter 
referred to as Xpert EID) as a consecutive test for specimens with an 
HIV-detected screening result on the CAP/CTM v2.0. Furthermore, 
we evaluate a novel approach to verifying indeterminate results, 
whereby discordant CAP/CTM v2.0 v. Xpert EID results define an 
indeterminate result, and compare this method with current practice 
of using Ct/RFI, to determine whether the indeterminate rate can be 
reduced without compromising diagnostic accuracy.
Methods
Study design
Accuracy of the Xpert EID assay as a second consecutive test for 
HIV diagnosis in infants was evaluated retrospectively. Results from 
infants with an HIV-detected CAP/CTM v2.0 result at birth (i.e. 
positive and indeterminate results) and a simultaneous Xpert EID 
birth test, and confirmed HIV infection status, were included in the 
study. Confirmed HIV status was determined by additional testing 
of follow-up blood samples using the CAP/CTM v2.0. Infants with 
a confirmed HIV-positive status were defined as having at least 
two HIV-detected virological results from separate samples taken 
at two different time points, as per National Department of Health 
guidelines.[23] Infants with a confirmed negative HIV infection 
status were defined as having two or more negative HIV PCR results 
following an initial HIV-detected result on screening at birth without 
any subsequent HIV-detected result thereafter.
Study setting
This evaluation was performed on laboratory data collected from four 
academic healthcare facilities situated in high-burden HIV prevalence 
settings in Gauteng Province, SA, between June 2014 and December 
2019. Charlotte Maxeke Johannesburg Academic Hospital, Chris 
Hani Baragwanath Academic Hospital, Kalafong Provincial Tertiary 
Hospital and Rahima Moosa Mother and Child Hospital were sites for 
an implementation study of HIV diagnostic point-of-care (PoC) testing 
whereby whole-blood samples were collected at the time of birth from 
HIV-exposed infants and tested concurrently using CAP/CTM v2.0 (in 
a centralised laboratory) and Xpert EID near PoC.
Study procedures
Laboratory data were extracted for all infants with a positive 
HIV PCR test at birth on the CAP/CTM v2.0, with concurrent 
testing performed on the Xpert EID. Confirmatory diagnostic results 
obtained from subsequent testing on a separate specimen were also 
extracted. To determine HIV status, clinic records and the NHLS 
Data Warehouse were searched for follow-up results. As SA does 
not have a unique patient identification system available at birth, 
the NHLS Data Warehouse was searched using patient demographic 
details and a validated probabilistic record-linking algorithm.[24]
Statistical analysis
Patient data, including demographic details, birth test (both CAP/
CTM v2.0 and Xpert EID) and follow-up HIV virological results 
(CAP/CTM v2.0) were exported from two REDCap databases 
(REDCap Consortium, Vanderbilt) of separate PoC implementation 
studies,[25] and imported into Microsoft Excel 2016 (Microsoft Corp., 
USA) for descriptive analysis. A two-by-two table was used to 
evaluate overall performance, determined as proportions with 95% 
confidence intervals (CIs), calculated using Stata 14.2 (StataCorp, 
USA), of the Xpert EID assay in predicting HIV status in infants 
with an HIV-detected CAP/CTM v2.0 screening test at birth. Finally, 
a novel approach to verifying indeterminate results was evaluated 
whereby discordant CAP/CTM v2.0 v. Xpert EID results were 
interpreted as indeterminate. This approach was compared with 
CAP/CTM v2.0 indeterminate results, as per NHLS resulting practice 
using the Ct/RFI cut-off, to describe the rate of indeterminate and 
false-positive results of the two approaches.
Ethical considerations
Permission to perform this study was granted by the Human 
Research Ethics Committee at the University of the Witwatersrand, 
Johannesburg (ref. nos M140639, M1711115 and M190645), and the 
University of Pretoria Research Ethics Committee (ref. no. 50/2018).
Results
A total of 172 HIV-exposed infants had an initial HIV-detected HIV 
PCR birth result on the CAP/CTM v2.0, and had a simultaneous 
Xpert EID test. Fig.  1 provides the study flow with inclusion and 
exclusion criteria. Of these infants, 150 met the inclusion criteria – an 
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HIV-detected CAP/CTM v2.0 birth test, a simultaneous test result 
obtained on the Xpert EID assay (including both HIV-undetected 
and HIV-detected results), and a confirmed HIV status as determined 
by subsequent virological testing performed on the CAP/CTM v2.0 
(Fig. 1). The median (interquartile range (IQR)) age at the time of birth 
testing was 1 (0 - 1) day. The median (IQR) age at the time of final HIV 
status was 1 (IQR 1 - 3) day for infants with an HIV-positive status and 
20 (IQR 7 - 43) days for infants with an HIV-negative status.
Of 150 infants with an initial HIV-detected CAP/CTM v2.0 screen-
ing test, 143 (95.3%) were found to have an HIV-infected status on 
follow-up (Table 1), of whom 139 (97.2%) had an HIV-detected result 
on Xpert EID at birth. Of the 7 (4.7%) infants with an HIV-uninfected 
status on follow-up, 6 (85.7%) tested HIV-undetected on Xpert at 
birth (Table 2). In a total of 6 infants (3.9%), the Xpert EID result at 
birth was discordant to HIV status on follow-up: 5 (3.3%) had a false-
negative and 1 (0.7%) a false-positive Xpert EID result. Birth testing 
performed on the latter infant at birth yielded positive test results on 
the CAP/CTM v2.0 and on the Xpert EID. Upon subsequent testing, 
results obtained from the infant on both assays were negative. Three 
months later, further testing was performed with an indeterminate 
test result received. Additional blood collected from this infant was 
tested on a single-copy assay with a result of <3 copies/1.5 million 
cells. At 510 days, treatment was halted with subsequent testing giving 
an HIV-negative result. The patient was followed up until 1 254 days, 
when HIV testing produced a negative result. As a second consecutive 
assay, the Xpert EID yielded a sensitivity of 96.5% (95% CI 92 - 98.9), 
specificity of 85.7% (95% CI 42.1 - 99.6), PPV of 99.3% (95% CI 95.7 - 
99.9), negative predictive value of 54.5% (95% CI 32.5 - 74.9), and 
overall accuracy of 96.1% (95% CI 91.5 - 98.5).
Eighteen infants (12.6%) had an indeterminate HIV PCR screening 
result on CAP/CTM v2.0 at birth, as verified by the NHLS. Upon 
subsequent testing on the CAP/CTM v2.0, 5 infants (27.8%) were 
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Fig. 1. Study flow showing eligible participants with final HIV status. (PCR = polymerase chain reaction; CAP/CTM v2.0 = Cobas AmpliPrep/Cobas TaqMan 
HIV-1 Qualitative Test v2.0; Ct = cycle threshold; Xpert EID = GeneXpert HIV-1 qualitative assay; NHLS = National Health Laboratory Service.)
Table 1. Comparison of initial HIV-1 result on the Xpert EID assay with HIV result on CAP/CTM v2.0
Final HIV status CAP/CTM v2.0 screening test result as per NHLS verification Xpert EID consecutive test result
HIV-positive (n=143) PCR-positive (n=130) HIV-detected (n=127)
HIV-undetected (n=3)
PCR-indeterminate (n=13) HIV-detected (n=11)
HIV-undetected (n=2)
HIV-negative (n=7) PCR-positive (n=2) HIV-detected (n=1)
HIV-undetected (n=1)
PCR-indeterminate (n=5) HIV-detected (n=0)
HIV-undetected (n=5)
CAP/CTM v2.0 = Cobas AmpliPrep/Cobas TaqMan HIV-1 Qualitative Test v2.0; NHLS = National Health Laboratory Service; Xpert EID = GeneXpert HIV-1 qualitative assay; 
PCR = polymerase chain reaction.
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found to have an HIV-negative status. All 
these infants had tested HIV-undetected 
on Xpert EID at birth. The remaining 13 
infants (72.2%) had an HIV-infected status, 
of whom 11 had an HIV-detected result on 
Xpert EID at birth. Using alternative criteria 
for verifying indeterminate results whereby 
specimens with discordant CAP/CTM v2.0 
v. Xpert EID results were interpreted as 
indeterminate, and concordant HIV-detected 
CAP/CTM v2.0 and Xpert EID results 
(regardless of Ct/RFI value) interpreted as 
HIV-detected, there would have been 11 
infants (7.2%) with an indeterminate birth 
result, of whom 5 (45.5%) would have been 
found to have an HIV-positive status on 
follow-up testing.
If reporting practice was informed by 
concordant or discordant qualitative CAP/
CTM v2.0 and Xpert EID results regardless 
of Ct/RFI value (Fig.  2), a drop in the 
indeterminate rate of 42.1% would have been 
achieved without increasing the rate of false-
positive results.
Discussion
This study demonstrated excellent PPV 
and overall accuracy of the Xpert EID as a 
second consecutive test for specimens that 
screened HIV-detected on CAP/CTM v2.0 
at birth. The Xpert EID result had reduced 
sensitivity when compared with the CAP/
CTM v2.0, and was discordant with final 
status in only 6 cases (3.9%), of which 5 
(3.3%) were false-negatives and 1 (0.7%) was 
a false-positive. The addition of the Xpert 
EID as a confirmatory test therefore provides 
an opportunity to improve the diagnostic 
accuracy and PPV of EID algorithms, thereby 
reducing the indeterminate rate and number 
of paediatric diagnostic dilemmas in SA. 
This is especially important at birth, as HIV-
infected infants increasingly demonstrate 
low-level viraemia and may test negative on 
subsequent samples as a result of exposure 
to antiretroviral prophylaxis and maternal 
ART. By reducing the indeterminate rate 
and providing prompt diagnosis, the volume 
of diagnostic dilemmas and time to ART 
initiation among infected infants will be 
reduced.
Because of a short analytical turnaround 
time of only 90 minutes, using the Xpert EID 
assay in the centralised EID laboratories for 
consecutive testing of all HIV-detected CAP/
CTM v2.0 results would result in minimal 
delays in result verification while potentially 
improving linkage to care and reducing 
loss to follow-up.[26,27] As the Xpert EID 
assay has been validated for both whole-
blood ethylenediaminetetra-acetic acid 
(EDTA) and dried blood spot (DBS) use,[28] 
the fact that DBS specimens represent the 
predominant sample type for EID in SA 
should not limit its use.
Study limitations
A number of important limitations need 
to be considered regarding these findings. 
Surprisingly, only 12.6% of infants had an 
indeterminate birth result, a much lower 
proportion than previously described, even 
among EDTA whole-blood samples.[13] 
This finding may reflect the small number 
of infants enrolled in the study, as well as 
challenges with obtaining follow-up results – 
13% of infants were excluded from the final 
analysis for this reason. Furthermore, analysis 
was restricted to whole-blood EDTA samples 
collected from HIV-exposed infants at birth 
from four facilities in Gauteng, and tested 
using a single laboratory assay, the CAP/CTM 
v2.0. As such, findings may not represent 
the overall EID programme. However, as 
intrauterine HIV-infected infants tested at 
birth have lower-level viraemia than older age 
groups,[14] and therefore have a higher rate of 
indeterminate HIV PCR results, it is likely 
that the Xpert EID assay would yield fewer 
false-negative results among older infants and 
children. Although testing was performed 
using EDTA whole blood and not DBS 
samples, which have been found to under-
quantify total nucleic acid compared with 
EDTA samples,[20] the use of DBS samples 
for the proposed new EID algorithm will not 
necessarily result in a higher indeterminate 
rate than demonstrated in this study. This 
is because the diagnostic sensitivity of DBS 
samples has been found not to be inferior 
to EDTA whole-blood specimens on Xpert 
EID,[29] and the same sample type would be 
used for consecutive testing.
Conclusions
The Xpert EID demonstrated excellent PPV 
and overall accuracy as a second consecutive 
test for specimens that yield an HIV-detected 
result on CAP/CTM v2.0. Incorporating 
the Xpert EID as a consecutive assay has 
the potential to enhance EID accuracy by 
Table 2. Comparison of initial HIV-1 result on the Xpert EID assay with final HIV 
clinical status
Xpert EID
HIV status on confirmatory testing
Positive       Negative Total 
Positive 138       1 139
Negative 5       6 11
Total 143       7 150
Xpert EID = GeneXpert HIV-1 qualitative assay.
1. Verify result as indeterminate
2. Request second sample to conrm status
HIV-exposed infant <18 months of age
Screening HIV PCR
HIV-detected HIV-undetected
Test remaining specimen 
on Xpert EID*
Follow EID testing guidelines – 
repeat testing according 
to age and breastfeeding
HIV-detected HIV-undetected
1. Verify result as positive
2. Manage patient as HIV-infected
3. Request second sample to conrm status
Fig. 2. Proposed new EID algorithm. (EID = early infant diagnosis; PCR = polymerase chain reaction; 
Xpert EID = GeneXpert HIV-1 qualitative assay; Ct = cycle threshold; *If sample is insufficient, interpret 
result according to Ct to differentiate positive from indeterminate results.)
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bringing down the rate of indeterminate results without increasing 
the false-positive rate, with minimal cost and delay in turnaround 
time.
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